Type 1 Diabetes Care and Management is a comprehensive virtual conference for adult and pediatric endocrine fellows interested in type 1 diabetes (T1D). T1D is a lifelong and often complex condition affecting an estimated 1.6 million people in the United States alone. Individuals with T1D are at greater risk of severe hypoglycemia, DKA, vascular complications, and diminished QOL. The field of T1D management is rapidly changing, with a growing number of insulin formulations, non-insulin therapies, technologies, and data platforms are reshaping how T1D is managed. With newer therapeutic, technological, and management advances, comes a multitude of clinical options that can be confusing and complex. Adding to this complexity is the workforce shortage among endocrinologists. The result is fewer providers able to address the complex needs of patients with T1D. Endocrine Society’s T1D fellows’ conference addresses these skill and workforce gaps with comprehensive education on T1D care while strengthening the network of next generation endocrinologists. This high-quality education is extended to practicing endocrinologists and medical professionals who are also in need of this training as an online course.

This course will contain three companion components:

• On-Demand Programs, Launches Saturday, March 20, 2021 – Includes 16 presentations from experts in the T1D field on topics including: Diagnosing and Understanding Risks of T1D; Principles in Insulin and Emerging Non-Insulin Therapies; Closing the Loop with Diabetes Technology; Screening, Preventing, and Treating Vascular Disease; Addressing Depression in T1D and Challenges across the Lifespan; Nutrition and Exercise in T1D Management; Caring for the Sick Patient at Home and in Emergency Situations; and a keynote presentation on Looking Back at 100 Years of Insulin from Jay Skyler, MD (University of Miami). Completion of the on-demand courses requires a pre-survey, a pre-test, recording, post-test, and evaluation to receive full credit.
• T1D Day, Thursday, April 22, 2021 – A live, virtual event for fellows who have watched the recordings to interact with through a live presenter Q&A, professional development session, T1D abstracts, devices demos and an exclusive virtual lunch discussion with program co-chairs Irl B. Hirsch, MD and Davida F. Kruger, MSN, APN-BC, BC-ADM.
• T1D Fellows Podcast, Launching in Summer 2021– A 30-minute podcast hosted by T1D experts Irl Hirsh and Davida Kruger discussing their approaches to managing patients with type 1 diabetes, with an emphasis on delivering optimal care in a virtual environment.

 
This education activity is supported by an independent medical educational grant from Abbott Diabetes Care, Inc., Dexcom, Inc., Helmsley Charitable Trust, Insulet Corporation, Lilly USA, Medtronic Diabetes, and Tandem Diabetes Care.
 

Upon successful completion these educational initiatives, participants should be better able to:

• Discuss the prevalence and progression of type 1 diabetes to recognize signs and differentially diagnose diabetes
• Devise individualized treatment strategies that use new and emerging insulin and non-insulin therapies to manage individuals with type 1 diabetes with and without common comorbid conditions.
• Incorporate diabetes technologies, including insulin pump therapy and continuous glucose monitoring, into treatment strategies for appropriate individuals with type 1 diabetes and evaluate data from those technologies.
• Recognize and evaluate individuals with type 1 diabetes for signs of depression and distress using updated guidelines and practice tools.
• Apply updated knowledge of treatments, practice guidelines, and clinical skills to improve care, long-term outcomes, and sick day management of individuals with type 1 diabetes.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 12.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC) - if eligible
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 12.00 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org

Irl B. Hirsch, MD - Program Co-Chair
University of Washington School of Medicine

Davida F. Kruger, MSN, APN-BC, BC-ADM - Program Co-Chair
Henry Ford Health System

Luisa Duran, MD
John Muir Health

Robert H. Eckel, MD
University of Colorado

Alison B. Evert, MS, RD, CDE
University of Washington

Satish Garg, MD
Barbara Davis Center

Janet B. McGill, MD, MA, FACE
Washington University in St. Louis

Michael C. Riddell, PhD
York University

Elizabeth Seaquist, MD
University of Minnesota

Jennifer Sherr, MD, PhD
Yale School of Medicine

Linda M. Siminerio, RN, PhD, CDE
University of Pittsburgh

Jill A. Weissberg-Benchell, PhD, CDE
Northwestern University

Jay S. Skyler, MD
University of Miami

STATEMENT OF INDEPENDENCE
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's Special Programs Committee (SPC). The commercial supporter(s) of this activity have no influence over the planning of this CME activity.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The following faculty reported the following relevant financial relationship(s) during the content development process for this activity:

 Irl B. Hirsch, MD (Co-Chair), has served as a research investigator for Beta Bionics, Medtronic Diabetes and Insulet and as a consultant/advisory board for Abbot Diabetes Care and Big Foot Biomedical.

Davida F. Kruger, MSN, APN-BC, BC-ADM (Co-Chair), has served on advisory boards and/or speaker bureaus for Abbott Diabetes Care, Dexcom, Eli Lilly and Company, Novo Nordisk, Pendulum Life, sanofi-aventis U.S. LLC, and Xeris.

Robert H. Eckel, MD, has served as a consultant and/or advisory board member to Kaleido Biosciences, Kowa American Corp., and Provention Bio, Inc.

Satish Garg, MD, has served on the advisory board for Novo Nordisk, Inc., Zealand, Medtronic, and Eli Lilly.

Janet B. McGill MD, MA, has received grant funding from Dexcom, Medtronic, and Novo Nordisk; has served as a consultant and/or advisory board for Bayer, Boehringer Ingelheim, Dexcom, Lilly, Metavant, Salix.

Anne L. Peters, MD, has served on an advisory board for Abbot Diabetes Care, Eli Lilly, Medscape, Merck, Novo Nordisk, Zealand; lecturer for Biorad; and received research funding from Dexcom.

Michael C. Riddell, PhD, has served as a consultant for Insulet Corporation, advisory board for Zucara Theraputics, received honoraria for Speakers' Bureau for Novo Nordisk, Eli Lilly, and Sanofi.

Jennifer Sherr, MD, PhD, has served as a consultant and/or advisory board member for Insulet, Lexicon, Bigfoot Biomedical, Cecelia Health and received research support from Medtronic Diabetes, Lilly Diabetes

Linda M. Siminerio, RN, PhD, CDE, has received research support from Becton Dickinson and Sanofi, and served on the advisory board for Abbott and Bayer.

The following faculty reported no relevant financial relationship: Luisa Duran, MD, Alison B. Evert, MS, RD, CDE, Elizabeth Seaquist, MD, and Jill A. Weissberg-Benchell, PhD, CDE, Jay S. Skyler, MD.

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This education activity is supported by an independent medical educational grant from Abbott Diabetes Care, Inc., Dexcom, Inc., Helmsley Charitable Trust, Insulet Corporation, Lilly USA, Medtronic Diabetes, and Tandem Diabetes Care.